Zantac burns big pharma
As Zantac litigation risk wipes $43bn off public company valuations are investors right to be worried?
Curevac muddies the Moderna/Arbutus waters further
The markets try to figure out who really benefits from last week’s patent decision over a key mRNA technology.
The Covid-19 vaccine battle just got interesting
A patent claim against Arbutus is thrown out, threatening parts of Moderna’s mRNA technology – including its Covid-19 vaccine.
Amarin falls at obvious hurdle
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
Holding a contingent value right in uncertain times
Though the stage is apparently set for Bristol’s contingent value right to pay out, the instrument trades at depressed levels.